1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

02 May 2024
Admin
News Article

Granules India gets US FDA approval for generic Mitigare capsules

Overview

Granules India received the US Food & Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA). This was filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of the company, for colchicine capsules, 0.6 mg. It is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Mitigare capsules, 0.6 mg of Hikma International Pharmaceuticals LLC (Hikma).

Colchicine indication:- Colchicine capsules are indicated for prophylaxis of gout flares in adults.

Approvals

Granules now have a total of 64 ANDA approvals from the US FDA. Of these 63, are final approvals and one is a tentative approval.

Current annual sale

The current annual US market for colchicine capsules is approximately $55 million, according to MAT February 2024, IQVIA/IMS Health.

Granules India

The Hyderabad-based Granules India set up in 1991 is a vertically integrated pharmaceutical company with advanced facilities.
The company said that it is one among the few in the world to be present in the manufacturing of the entire value chain from active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs).

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!